Cambridge, MA30+ days ago
Its lead asset, zolucatetide (FOG-001), is a first-in-class, clinically validated direct inhibitor of the interaction between ß-catenin and the T-cell factor (TCF) family of transcription factors, implicated in millions of cancer cases annually, including in colorectal cancer, desmoid tumors, hepatocellular carcinoma and a range of other Wnt/ß-catenin-driven tumors. Reporting to the VP of Discovery DMPK, you will serve as the primary DMPK representative on cross-functional discovery project teams, collaborating closely with medicinal chemists, pharmacologists, toxicologists and external CRO partners to advance novel therapeutics from early discovery through DC nomination.